Alli hits Europe, beefing up GSK's consumer line

GlaxoSmithKline launched its nonprescription weight-loss drug alli in European pharmacies, boosting its line-up of consumer products in the region. Glaxo is eyeing its OTC meds for growth at a time when prescription drug sales are slowing down. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.